Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

OneSource Specialty Pharma Earnings Call: Key Takeaways

Onesource Q4 FY26 shows strong sequential recovery driven by semaglutide drug-device combination launches, although annual profits were dragged down by prior delays and exceptional items.

Why this was an Alfa AlertNot a filter event. Results indicate recovery from a weak Q3 rather than a material beat over original guidance.
Highlights
Revenue growth47% QoQ growth; full-year revenue down 2% YoY due to delays.
MarginsSequential margin expansion of 1,550 bps; aiming for structural 40%.
Demand visibilityStrong visibility for GLP-1s; customer capacity reservation through prepayments.
Management confidenceHighly confident, emphasizing regulatory track record and market share in India.

Growth

Revenue grew 47% QoQ to ₹4,282 million; EBITDA rose over 5x sequentially due to operating leverage.

Outlook

Reiterated FY28 guidance: $400 million organic revenue with approximately 40% EBITDA margins.

Risks

Deferral of Steriscience merger due to valuation concerns; reliance on a single high-growth molecule (semaglutide).

Source

Earnings Call filed with NSE, NSE: ONESOURCE. Summary written with AI assistance from the document.

Read the document ↗

OneSource Specialty Pharma Ltd: key numbers

Share price
₹1,602.60
Market cap
₹18,377 Cr
Revenue (annual)
₹1,422 Cr
Net profit (annual)
₹-73.80 Cr
P/E (TTM)
-378.0×Sector 50.4×
Promoter holding
30.48%+0.00% QoQ
FII holding
19.19%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from OneSource Specialty Pharma Ltd

All →
19:39 IST BSE
Employee Stock Options

OneSource Specialty Pharma Employee Stock Options

Onesource Specialty Pharma Limited has allotted 900 equity shares under its Employee Stock Option Plan. This allotment updates the company's total paid-up share capital.

19:26 IST NSE
Employee Stock Options

OneSource Specialty Pharma Employee Stock Options

OneSource Specialty Pharma allotted 900 shares under its ESOP 2021 scheme at an exercise price of ₹278 per share, totaling ₹0.03 Crore.

Value
₹0.03 Cr
23:02 IST BSE
Management Change

OneSource Specialty Pharma Management Change

Onesource Specialty Pharma Limited appointed B S R & Co LLP as its Statutory Auditor for a 60-month term, effective September 23, 2026.

23:39 IST BSE
Other Announcement

OneSource Specialty Pharma Other Announcement

OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.

23:34 IST BSE
Annual General Meeting

OneSource Specialty Pharma Annual General Meeting

OneSource Specialty Pharma held its 19th Annual General Meeting on September 23, 2026. Shareholders transacted ordinary and special business items, including re-appointments and related party approvals.

17:02 IST BSE
Annual General Meeting

OneSource Specialty Pharma Annual General Meeting

OneSource Specialty Pharma issued an addendum to its 19th AGM notice regarding additional disclosures for agenda items about material related party transactions.